Acrivon Therapeutics, Common Stock Today
| ACRV Stock | 5.53 0.15 2.79% |
PerformanceVery Weak
| Odds Of DistressLow
|
Acrivon Therapeutics, is selling for under 5.53 as of the 26th of February 2025; that is 2.79 percent up since the beginning of the trading day. The stock's lowest day price was 5.31. Acrivon Therapeutics, has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of November 2022 | Category Healthcare | Classification Health Care |
Acrivon Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 31.14 M outstanding shares of which 1.1 M shares are presently shorted by private and institutional investors with about 29.98 trading days to cover. More on Acrivon Therapeutics, Common
Moving against Acrivon Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Acrivon Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsAcrivon Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Acrivon Therapeutics,'s financial leverage. It provides some insight into what part of Acrivon Therapeutics,'s total assets is financed by creditors.
| |||||
Acrivon Therapeutics, Common (ACRV) is traded on NASDAQ Exchange in USA. It is located in 480 Arsenal Way, Watertown, MA, United States, 02472 and employs 58 people. Acrivon Therapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 172.18 M. Acrivon Therapeutics, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 31.14 M outstanding shares of which 1.1 M shares are presently shorted by private and institutional investors with about 29.98 trading days to cover.
Acrivon Therapeutics, generates negative cash flow from operations
Check Acrivon Therapeutics, Probability Of Bankruptcy
Ownership AllocationAcrivon Therapeutics, holds a total of 31.14 Million outstanding shares. The majority of Acrivon Therapeutics, Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Acrivon Therapeutics, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Acrivon Therapeutics,. Please pay attention to any change in the institutional holdings of Acrivon Therapeutics, Common as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Acrivon Ownership Details
Acrivon Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-12-31 | 117.3 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 113.8 K | |
| Dafna Capital Management Llc | 2024-12-31 | 112.4 K | |
| Ubs O'connor Llc | 2024-12-31 | 102.8 K | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 74.6 K | |
| Jpmorgan Chase & Co | 2024-09-30 | 68 K | |
| Baker Bros Advisors Lp | 2024-12-31 | 52.9 K | |
| Renaissance Technologies Corp | 2024-12-31 | 49.4 K | |
| Barclays Plc | 2024-12-31 | 38.1 K | |
| Ra Capital Management, Llc | 2024-12-31 | 8.3 M | |
| Perceptive Advisors Llc | 2024-12-31 | 5.4 M |
Acrivon Therapeutics, Historical Income Statement
Acrivon Stock Against Markets
Acrivon Therapeutics, Corporate Management
| Peter MD | Chairman, CoFounder | Profile | |
| Jesper Olsen | Head CoFounder | Profile | |
| Dr MBA | Senior Affairs | Profile | |
| Katharine CPA | Vice Accounting | Profile | |
| Bruce Close | Vice Compliance | Profile | |
| MaryAlice JD | Chief Officer | Profile | |
| Crystal Mercado | Global HR | Profile |
Already Invested in Acrivon Therapeutics, Common?
The danger of trading Acrivon Therapeutics, Common is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Acrivon Therapeutics, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Acrivon Therapeutics,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Acrivon Therapeutics, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.